Sarver Heart Center

Paulo Pires

Assistant Professor, Physiology
Assistant Professor, Surgery
Member of the General Faculty
Member of the Graduate Faculty
Primary Department
Department Affiliations
Contact
520-626-8632

Work Summary

Dr. Pires is an Assistant Professor and Principal Investigator in the Department of Physiology, University of Arizona College of Medicine Tucson. Dr. Pires received his Ph.D. in Pharmacology and Toxicology at Michigan State University and completed his training as a Postdoctoral Fellow at the University of Nevada, Reno School of Medicine. Throughout his career Dr. Pires has published numerous research articles on the impact of chronic cardiovascular diseases in development of cerebral vascular disorders, such as ischemic strokes, as well as mechanisms regulating cerebral vascular function. In his laboratory, Dr. Pires' research focuses on the vascular component underlying neurodegenerative diseases, such as cerebral amyloid angiopathy and Alzheimer's diseases, as well as the brain waste clearance system, the glymphatic / cervical lymphatic system.

Research Interest

Research in Dr. Pires's laboratory follows his training and expertise in the cerebral microcirculation, and focuses on investigating the role of ion permeable molecular sensors expressed in endothelial cells, both arteriolar and capillary, in the control of localized blood perfusion in the brain, physiologically induced by neuronal stimulation. This interest is coupled with his long-standing scientific passion in elucidating the molecular mechanisms underlying cerebrovascular disorders related to the development of dementia, such as aging, cerebral amyloid angiopathy, Alzheimer's disease and traumatic brain injury. To progress in these projects the Pires lab have developed and is systematically characterizing a mouse strain with endothelial cell-specific knockout of the N-Methyl-D-Aspartate receptor (cdh5:Grin1-/-). Further, the lab has established aging colonies of different mouse models of hypercholesterolemia, cerebral amyloid angiopathy and Alzheimer’s disease, together with respective wild-type littermates, including ApoE3 / ApoE4 knock-in, Tg-SwDI (a model of cerebral amyloid angiopathy), and the 5x-FAD (a model of early-onset Alzheimer’s Disease with prevalence of parenchymal amyloidosis). Further, the Pires lab has a colony of mice expressing the genetically encoded calcium indicator GCaMP8 in endothelial cells (cdh5:GCaMP8), acquired from Dr. Michael Kotlikoff at Cornell University. Lastly, we have successfully implemented AAV-BR1 viral transfection of cerebral endothelial cells using a GFP reporter, we are currently expanding the use of this tool to perform cerebral artery endothelial cells-specific knock-in / knock-out of targets of interest. In recent years the Pires laboratory has started studying the function of the waste clearance system of the brain (the glymphatic system), and its impact and potential therapeutic potential in neurodegenerative diseases. This is an exciting novel area of research involving highly integrative studies, starting at the molecular / cellular signaling level and expanding to whole animal physiology and behavior. Taken together, the long-term goal of the Pires laboratory is to perform translational, clinically relevant scientific investigation of how chronic neurodegenerative diseases, as well as acute traumatic events, affect the cerebral circulation and increase the risk of developing severe dementia, with the hopes of identifying novel therapeutic targets to improve the lives of the affected population.

Steven Goldman

Professor, Medicine - (Research Scholar Track)
Research Scientist
Professor, BIO5 Institute
Primary Department
Department Affiliations
Contact
(520) 626-2939

Work Summary

Our lab has a new treatment for heart failure. We have a biodegradable graft seeded with adult human cells that we put on the surface of the heart. The potential is to regenerate new heart muscle

Research Interest

Research in my laboratory over the last 30 years has focused on chronic heart failure (CHF), its pathophysiology and the development of new treatments for CHF. We have developed clinically relevant animal models of heart failure that allow us to explore the translational potential of new treatments. Our work initially examined the role of afterload reduction and neurohormal blockade. More recently we have been working with cell-based therapy for CHF using bioengineered scaffolds to prevent left ventricular (LV) remodeling and restore function in the damaged heart. Our most effective scaffold is a biodegradable vicryl mesh with embedded viable neonatal fibroblasts that secrete angiogenic growth factors. This patch increases myocardial blood flow, improves LV systolic function, and reverses LV remodeling if implanted at the time of an acute myocardial infarction. In CHF, this patch still improves myocardial blood flow but does not improve LV function or reverse LV remodeling. Thus, we have an effective delivery system for cell based therapy for CHF that increases myocardial blood flow and provides structural support for new cell growth. We are now focusing on seeding this patch with human inducible pluripotent stem cells in the cardiac lineage, the seeded cardiomyocytes align, communicate, contract in a spontaneous and rhythmic fashion. When implanted in rats with CHF, they improve LV function. We are exploring this patch seeded with human inducible cardiac pluripotent stem cells to treat patients with CHF. Keywords: induced pluripotent stem cells